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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease aﬀecting particularly motor neurons for which no cure
or eﬀective treatment is available. Although the cause of ALS remains unknown, accumulative evidence suggests an autoimmune
mechanism of pathogenesis. In this paper, we will summarize the current research related to autoimmunity in the sporadic form
of ALS and discuss the potential underlying pathogenic mechanisms and perspectives. Presented data supports the view that
humoral immune responses against motor nerve terminals can initiate a series of physiological changes leading to alteration of
calcium homeostasis. In turn, loss of calcium homeostasis may induce neuronal death through apoptotic signaling pathways.
Additional approaches identifying specific molecular features of this hypothesis are required, which will hopefully allow us to
develop techniques of early diagnosis and eﬀective therapies.
1. Introduction
Amyotrophic lateral sclerosis is a neurodegenerative disorder
characterized by a progressive death of motor neurons result-
ing in fatal paralysis in a few years. ALS was well described
by Jean-Martin Charcot in 1869. Since that time, numerous
studies have been conducted to characterize the anatomical,
physiological, and molecular properties of the disorder [1–
4]. A number of genes have been identified in hereditary ALS
(named familial ALS), which account for 10% of the cases
[5, 6]. The remaining 90% is called sporadic ALS and does
not show any conventional hereditary pattern. Similar eﬀorts
have been done searching for a therapeutic strategy without
success [7–13]. To date, the pathogenic mechanisms of ALS
continue being unknown.
In this paper, we will summarize the current evidence
related to autoimmunity in the sporadic form of ALS and
discuss the potential underlying pathogenic mechanisms and
perspectives.
2. Pathogenesis
The mechanisms of the specific neuronal death in ALS are
unknown. Nevertheless, numerous observations support the
involvement of certain alterations such as an increase in the
intracellular Ca2+ concentration ([Ca2+]i) [14–18], excito-
toxicity mediated by glutamate [19–22]; generation of free
radicals [23–27], and autoimmunity. Recently, more atten-
tion has been called to protein inclusions in the cytoplasm
of degenerating motoneurons [28]. One of the components
of these ubiquitinated aggregates was identified as being TAR
DNA-binding protein (TDP)-43 [29, 30], which was found
to be mutated in some familial and sporadic ALS patients
[31].
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Although these potentially pathogenic mechanisms are
generally investigated separately, it is reasonable to consider
that they can be part of a series or parallel events leading
to neuronal death. Actually, an increase in [Ca2+]i may
enhance the generation of free radicals and the release of
glutamate and in turn increase [Ca2+]i further [32, 33].
Nonetheless, most of the studies of ALS provide evidence
of mechanisms associated with the disease but it is not clear
whether those alterations are pathogenic or a nonpathogenic
epiphenomenon.
Morphological, biochemical, pharmacological, and phys-
iological studies performed either in animal models, cell
culture, or with ex vivo preparations support the existence
of autoimmune mechanisms in ALS [14–18, 34–38]. Typical
hallmarks of autoimmunity such as circulating immune
complexes, higher frequency of a particular histocompatibil-
ity type, or association with other autoimmune diseases have
been reported [39–41].
3. Humoral Factors and Antibodies from
ALS Patients That Affect Motoneurons
3.1. Eﬀect of Sera and Purified Antibodies Using In Vitro and In
Vivo Systems. Most studies have been carried out examining
the eﬀect of sera or purified antibodies from ALS patients
searching for general autoimmune markers aimed at identi-
fying the pathogenic mechanisms, a necessary step towards
therapy development. The earliest studies reported that sera
from ALS patients induced demyelination, killed or dam-
aged spinal or cerebellar cultured neurons [42–44] whereas
Horwich and colleagues [45] did not observe such eﬀects on
motoneuron cultures. The interpretation of these data may
be diﬃcult because serum is complex and undefined, and the
experimental conditions may induce opposite eﬀects regard-
less of the humoral factors potentially associated with ALS.
It is known that cultured cells may be particularly vulnerable
to noxious stimuli and that serum applied on cell cultures
promotes cellular survival [46]. Other studies also showed
that antibodies from ALS patients (ALS-Abs) presented
immunoreactivity against myelin [47]. An approach aimed at
examining specifically the sera eﬀect and attempting to avoid
any unspecific eﬀect owing to the vulnerability of cultured
cells was performed by Liveson and colleagues [48]. This
study examined the eﬀect of sera on organotypic cultures of
spinal cord, and a slight myelinotoxic activity was detected
only in 2 of 11 sera tested [48]. An additional study using
purified ALS-Abs in organotypic spinal cord cultures showed
no changes in the number and morphology of ventral horn
neurons after a treatment as long as three weeks with ALS-
Abs [49]. Strikingly, these studies examined only the eﬀect
of the sera or ALS-Abs on the cell body of motoneurons but
not at themotor nerve terminal. Indeed, several alterations in
ALS patients have been reported at the synaptic level [50–54]
which is consistent with the physiological andmorphological
alterations reported in the neuromuscular junction (NMJ)
from in vivo and ex vivo mouse and rat preparations [18, 34,
35, 38, 55–58].
Muscular fatigue, muscle denervation, and alterations in
synaptic transmission, such as a decrease in the frequency
and amplitude of the miniature end-plate potentials
(MEPPs) and higher quantal content (QC) compared with
control individuals, have been consistently observed in
patients with ALS [50–52, 59, 60]. Acute treatment of mus-
cles with ALS-Abs increased the frequency of spontaneous
and asynchronous transmitter releases in mouse or rat neu-
romuscular preparations [18, 34, 35, 55, 56, 58]. Although
the acute exposure of the neuromuscular preparations to
ALS-Abs induced an increase in MEPPs frequency, it is
feasible that a longer exposure may result in a reduction
of MEPPs frequency as observed in ALS patients [52]. This
idea is consistent with studies on the long-term eﬀect of
ALS-Abs [35]. Application of ALS-Abs on the levator auris
muscle by subcutaneous injection during 4 to 12 weeks also
increased the frequency of MEPPs in five out of seven ALS-
Abs tested, and all of them produced significant changes in
the quantal content of evoked neurotransmitter release. In
muscles treated with the antibodies from one of the ALS
patients, synaptic activity was completely absent and it was
consistent with histological studies demonstrating complete
denervation. Axonal degeneration and denervation were
present in most muscles treated with ALS antibodies, but not
in muscles treated with control antibodies [35]. Thus, ALS-
Abs appear to lead to long-lasting eﬀects at the neuromus-
cular junction ranging from an increase of the frequency of
MEPPs to complete disruption of neurotransmission.
Additional electrophysiological studies on mouse mus-
cles treated with ALS-Abs have revealed synaptic changes
in the molecular machinery involved in neurotransmission
[38]. Neuromuscular transmission, in physiological condi-
tions, is mediated by P/Q-type voltage-dependent calcium
channels (VDCC) [61, 62]. However, after several weeks of
treatment with ALS-Abs, the neuromuscular transmission is
mediated by P/Q-type and L-type VDCC. The L-type VDCC
is expressed in motor nerve terminals [63]; however, this
channel only participates in synaptic transmission in stages
of high synaptic remodeling, such as after treatment with
botulinum toxin type A, regenerating NMJ after crash of
motor nerve and rodent neonatal muscles where maturation
of NMJ takes place [62, 64–66]. The functional coupling of
L-type VDCC [38] not only shows that the ALS-Abs may
induce functional alterations, but also provides evidence of
specific molecular and physiological synaptic modifications
associated with NMJ regeneration. This is consistent with
denervation and reinnervation changes observed in the
SOD1 (superoxide dismutase-1) animal model and ALS
patients [54].
The interaction of ALS-Abs with motor nerve terminals
was suggested by experiments showing the capability of ter-
minals to preferentially uptake those antibodies, compared
with control antibodies in mice [37, 57], and also by the
detection of internalized antibodies in spinal cord and motor
cortex of patients with ALS and in animal models [67–
69]. The internalization of ALS-Abs was expected to occur
by interaction with nerve terminals, since uptake by nerve
terminals is a normal process for molecules that bind
to them, such as tetanus and cholera toxins, antibod-
ies raised against synaptosomes, or inorganic mercury [70–
73]. Recently, by using ALS-Abs as primary antibodies in
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immunofluorescence experiments, it was shown that the
IgGs purified from ∼50% of the ALS patients presented
immunoreactivity against the presynaptic membrane of
motor nerve terminals and induced synaptic potentiation
[18].
Demestre and colleagues have reported that motor neu-
rons are susceptible to apoptosis through activation of cas-
pase 3 when motor neuron cultures are treated with ALS-
Abs, compared with control-IgGs [74]. These results are in
accordance with previous studies in cell culture systems like
the VSC4.1 hybrid motor neuron cell line [75], a human
neuroblastoma cell line [76], and primary rat brain and
spinal cord cultures [76]; in addition, ALS-Abs enhanced cell
death in the A127 glioblastoma cell line [77].
3.2. Antibodies against Voltage-Dependent Calcium Channels.
Biochemical and electrophysiological evidence suggested
that antibodies from 40 to 60% of ALS patients show
immunoreactivity against VDCC. For instance, immunore-
activity against L-type VDCC purified from muscle fibers
(Cav1.1) and a reduction in Ca2+ currents were reported [78–
80]. However, these observations may not be underlying the
alterations reported on synaptic transmission because of a
number of reasons. First, increased neurotransmitter release
is expected to be associated with an increase instead of a
reduction in Ca2+ currents [81, 82]. Second, the cytotoxic
eﬀect of the ALS-Abs on culturedmotoneurons was inhibited
by P/Q- and N-type VDCC blockers, but not L-type blockers
[44]. Third, therapeutics trails using L-type VDCC blockers
like verapamil or nimodipine did not aﬀect the progression
of the disease [83, 84]. Fourth, L-type VDCC is not normally
coupled to synaptic transmission [62, 85–87]. However,
recent investigations in our laboratory showed that L-type
VDCC regulates synaptic vesicle recycling [88], suggesting
that even when the channel is not directly coupled to synaptic
transmission, it can aﬀect synaptic vesicle availability, and in
turn, neurotransmitter release.
Biochemical evidence from Kimura and colleagues
showed that ALS-Abs bind to L-type VDCC and blocks the
interaction of the monoclonal antibody (8B7mAb) against
L-type channels, suggesting overlapping epitopes of the two
antibodies. However, Nyormoi provided evidence indicating
that Kimura’s observations were not due to ALS-Abs; he
claimed that destruction of the antigen by serine proteases
copurified with the IgG prevented the interaction of the
8B7mAb with the VDCC [89]. Nevertheless, it was shown
recently that serine proteases from ALS sera have similar
cytopathological eﬀects to those obtained from healthy
subjects, which are distinct from those observed after ALS
IgG passive transfer [90].
Besides the eﬀect of ALS-Abs linked to L-type channels
[78–80], other authors found that ALS-Abs increased P/Q-
type Ca2+ currents in Purkinje cells [91] or decreased Ca2+
currents of cultured granule cells [92] or shifted to the left the
activation curve of Ca2+ current in cultured rat motoneurons
[93]. Thus, these results suggest that ALS-Abs modify Ca2+
currents, but the particular eﬀect depends on the cellular
type and not on the types of VDCC [93–95]. Hence, it is pos-
sible to conclude that somehow ALS-Abs may modify Ca2+
currents but it is not clear if the antibodies interact directly
with VDCC or modify Ca2+currents by interacting with
another molecule capable of regulating Ca2+ currents. For
instance, G-protein-coupled receptors are strong modulators
of the family 2 of VDCC (i.e., Cav2.1, Cav2.2, and Cav2.3)
[96] and recent evidence shows that receptor tyrosine kinase
regulates VDCC through p21-ras and ERK 1/2 [97, 98].
Consistently, biochemical and physiological experiments did
not detect immunoreactive ALS-Abs against VDCC [99, 100]
or eﬀects on synaptic transmission mediated by interaction
with VDCC [18].
In support of the existence of antibodies directed against
calcium channels or related proteins, our recent studies
showed that the absence of P/Q-type channel α1 subunits
reduces ALS-IgG binding to mouse NMJs and suppresses
antibody eﬀects on spontaneous acetylcholine release. These
experiments further indicate that IgGs from ALS patients
would react with a putative protein that depends on the P/Q-
type channel presence at the mouse neuromuscular junction
(Gonzalez L. et al., unpublished data).
3.3. Antibodies against Other Molecular Targets. Diﬀerent
investigations have provided evidence indicating that a pro-
portion of patients with ALS have antibodies directed against
other targets such as neurofilaments, Fas receptor (CD95),
fetal muscular proteins, and vascular antigens [76, 79,
101–106]. The potential role of those antibodies has not
been investigated as much as antibodies potentially directed
against VDCC. Actually, the evidence suggests that ALS-Abs
may be directed to an unknown molecule that in turn may
modify Ca2+ currents and Ca2+ homeostasis. Thus, since
in the SOD1 mutant mice a pathway downstream of Fas
is involved in motor neurons death and also these mice
show higher sensibility to activate the pathway [107, 108],
the Fas receptor could be a candidate to investigate further.
Nonetheless, a recent study in this animal model suggested
that this familiar form might not be associated with a
deregulation in the immune system, as SOD1 mutant mice,
which were also B cell deficient (i.e., μMT/SOD1), did not
show altered mortality or rotarod performance compared
with the single mutant SOD1 [109]. On the other hand,
antibodies against neurofilaments, fetal muscular proteins
and vascular antigens seem to be more likely markers of
an autoimmune disorder owing to the fact that they are
directed to intracellular or systemic proteins [110]. Taken
together, is clear that a complete screening to identify one
or more molecular targets for antibodies from ALS patients
is required. The recent development of the proteomics
technology will help enormously in this task. The identi-
fication of antigens for ALS-Abs is currently underway in
our laboratory. The identification of one or more antigenic
targets will provide a system to develop a specific ALS animal
model and determine the precise role of autoimmunity in
ALS as well as therapeutic approaches.
3.4. Alteration of Calcium Homeostasis by ALS Antibod-
ies. Besides controversies related to the molecular target
of ALS-Abs, calcium homeostasis alterations and associ-
ated structural changes were consistently reported. Using
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immunohistochemistry and electronmicroscopy techniques,
it has been shown that ALS-Abs enhance [Ca2+]i and struc-
tural alterations in motor nerve terminals as well as in cell
bodies of spinal motoneurons after intraperitoneal or intra-
muscular injection in mice [14, 16, 17]. Of note, ALS-Abs
produced dose-dependent calcium increases either in axon
terminal synaptic vesicles and mitochondria or in rough
endoplasmic reticulum, mitochondria and Golgi. Moreover,
increased mitochondrial volume and increased number of
synaptic vesicles compared to any of the disease control
groups were detected [14–16]. Worth mentioning, similar
structural modifications and increased [Ca2+]i were observed
in motor nerve terminals in muscle biopsies from ALS
patients [15]. About 70% of ALS-derived IgGs induced the
appearance of a population of motoneurons with electron
lucent cytoplasm, distended Golgi, disrupted Nissl’s bodies
andmitochondria (i.e., necrosis). However, 30% of ALS-IgGs
additionally induced electron-dense degeneration in 40% of
motoneurons [17]. These neurons exhibited shrinkage and
condensed nuclear chromatin and resembled preliminary
stages of apoptosis. Owing to the well-known eﬀects of
[Ca2+]i homeostasis deregulation [111] and the correlation
between [Ca2+]i increment and structural changes [14, 16,
17], these data suggest that the increased [Ca2+]i is respon-
sible for the structural changes. Moreover, the mechanisms
underlying increased [Ca2+]i may be those detected to
enhance synaptic transmission in motor nerve terminals
[17]. The activation of this increased neurotransmitter
release required a non-constitutive Ca2+ influx through N-
type (Cav2.2) calcium channels and phospholipase C activity.
Once the ALS-Abs-induced synaptic potentiation is started,
the calcium influx through VDCC is no longer required.
Instead, the activation of the inositol 1,4,5-trisphosphate
receptors (IP3R) and ryanodine receptors is necessary to both
activate and sustain the increased neurotransmitter release
[18].
In contrast, no changes in [Ca2+]i by ALS-Abs applica-
tion was observed in synaptosomes from cerebral cortex of
rat, measured by Fura 2 Ca2+ imaging [112]. These exper-
iments support the hypothesis that ALS-Abs have specific
targets and tissue specificity, providing a clear mechanism for
the selective vulnerability of motoneurons in ALS. In other
words, ALS-Abs may aﬀect [Ca2+]i in motor nerve terminals
but not in nerve terminals from the cerebral cortex. Other
experiments provide additional evidence arguing in favor
of tissue specificity. Although ALS-Abs aﬀect motor nerve
terminals, both morphologically and physiologically, they do
not aﬀect spinal cord organotypic cultures. Similar eﬀects
are observed after either intraperitoneal or intramuscular
injection of ALS-Abs, and immunoreactivity of ALS-Abs was
only reported against NMJ [16–18, 48, 99].
4. Animal Models
Autoimmune animal models of ALS have been developed
by inoculation of purified motoneurons [67] or spinal cord
ventral horn homogenate to Guinea pigs [68, 113]. In both
models, inoculated material was obtained from bovine. The
experimental autoimmune motor neuron disease (EAMND)
results in lower motoneuron signs [67], while the experi-
mental autoimmune gray matter disease (EAGMD) results
in both upper and lower motoneuron destruction [68, 113].
To generate the ALS autoimmune models, antigens were
injected into Guinea pigs 4 times at 4-week intervals. An
increase of the frequency of MEPPs and loss of motoneurons
within the spinal cord were observed two months after the
last immunization. In this animal model, immunoreactivity
against IgG at spinal cord motoneurons and at the endplates
were detected, showing accumulation of antibodies and
suggesting autoimmunity as a pathogenic mechanism. The
animal model originally developed by Engelhardt and col-
leagues [69] has been recently reproduced in a study that
showed convincing evidence of upper and lowermotoneuron
damage, from which the involvement of oxidative stress in
the neuronal degeneration was suggested [113]. The EAGMD
is the model that better resembles ALS because it is char-
acterized with loss of motoneurons, the presence of dener-
vation, inflammatory foci within the spinal cord, IgG within
motoneurons, and electrophysiological abnormalities of the
neuromuscular junction [52, 55, 68, 114, 115].
If the mechanisms involved in the ALS animal model and
ALS patients are equivalent, the antibodies purified from the
ALS animal model should mimic the eﬀect of the antibodies
purified from patients. Noticeably, both the antibodies from
ALS patients and the ALS animal model injected in mice
produced limb weakness, increase of the frequency of MEPPs
and presence of immunoreactivity for IgG at the NMJ and
motoneuron cell bodies [55]. The similarities between the
eﬀects induced by antibodies from the ALS animal model
and patients strongly support an autoimmune etiology for
this disorder.
5. Hallmarks of Autoimmunity in ALS
Since autoimmune mechanisms have been considered as
a pathogenic factor in ALS, several laboratories started to
look for typical signs or hallmarks of autoimmune diseases
such as immunological alterations and associated disorders.
The proportion of lymphocyte subsets has been reported
to be normal in ALS patients [116]. However, 19% of
ALS patients and around 20% of their relatives presented
thyroid disease [41]. Furthermore, interesting but contro-
versial observations had been reported. High frequency of
the HLA (human leukocyte antigen) A3 and HLA B12
histocompatibility antigens was found in ALS patients with
rapid and slow progression, respectively [39], but it was not
detected in other patients [117]. Similarly, an increased
incidence of immune complexes in serum and kidney was
detected by one laboratory [40] but not by another [117].
In ALS, a systemic inflammatory response is not report-
ed. However, there is evidence suggesting that neuroinflam-
mation may be a pathological characteristic of this disease
[114, 118–120]. An important marker of autoimmunity
is the prevalence and extent of T lymphocytic infiltration
in the ventral horn of the spinal cord from ALS patients
[114]. Using monoclonal antibodies against macrophages T
and B cells, the authors revealed that as high as 79% of
the specimens showed a cellular mononuclear infiltration.
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Tissue samples from other ALS subjects with the same dura-
tion and clinical signs did not show lymphocytic infiltration,
suggesting that it is unlikely that such infiltrates appear as a
consequence of spinal cord atrophy. The cellular composition
of the spinal cord inflammatory infiltrate comprises a sup-
pressor/cytotoxic T-cell subset andmacrophages (in the ante-
rior and lateral corticospinal tracts and anterior horns) [118].
Similarly, Engelhardt and colleagues [119] observed T-helper
cells (in proximity to the corticospinal tract degeneration) and
T-helper and T-suppressor/cytotoxic cells (in ventral horns).
Other laboratories also observed that inflammation in ALS
spinal cord as well as in cortex is based on macrophages
and T cells [120]. Additional evidence pointing towards an
involvement of autoimmune processes has been the recent
finding of increased levels of interleukins IL-17 and IL-
23 in serum and cerebrospinal fluid of ALS patients. This
increment is thought to be a sign of Th-17 activation, a subset
of T cells suggested to be crucial in destructive autoimmunity
[121].
Recent studies have shown that microglia/macrophage
activation and immune reactivity is relatively common in
spinal cord tissues of patients with ALS and the SOD1
animal model [122, 123]. The presence of immature and
activated-mature dendritic cells (i.e., CD1a and CD83 pos-
itive cells) was detected in ventral horn and corticospinal
tracts from ALS individuals. Monocytic, macrophage, and
microglial transcripts (CD14, CD18, SR-A, and CD68) were
increased in ALS spinal cord, and activated CD68(+) cells
were shown in close proximity to motor neurons. The
expression of the chemokine MCP-1 (monocyte chemotactic
protein-1), which attracts monocytes and myeloid dendritic
cells, and of the cytokine macrophage-colony stimulating
factor (M-CSF) was also increased in ALS tissues. The rate
of disease progression positively correlates with the detection
of dendritic cell transcripts [122]. This observation along
with extensive spinal cord microglial/macrophage activation
before the onset of clinical symptoms [124] and prior to
evidence of significant motor neuron loss in an ALS mouse
model suggests that systemic immune deregulation plays
a key role in ALS.
It is interesting to note the existence of other disorders
similar to ALS, such as the ALS-like autoimmune syndromes.
The best characterized is the multifocal motor neuropathy
(MFMN) [125] that manifests as asymmetric muscular
weakness with slow progression aﬀecting preferentially
distal muscles. In patients with MFMN, signs of upper
motoneuronal compromise are not observed. The diagnosis
is confirmed on the base of motor nerve conduction block
or an increase in the level of antibodies against ganglioside
GM1. These antibodies cause the classical physiological
changes in this syndrome [126, 127]. This conclusion is
based on the excellent response of the patients to immuno-
suppressive therapy with cyclophosphamide or intravascular
immunoglobulin [125].
6. Immunosuppressive Therapy in ALS
The ultimate and paramount objective of the investigation
in ALS is to develop a therapeutic treatment. Many diﬀerent
therapeutic trials have been performed; most were based on
various hypotheses of mechanisms for neuronal death, in-
cluding oxidative damage, loss of trophic factor support,
glutamate-mediated excitotoxicity, and chronic inflamma-
tion [13]. The discovery of a group (∼3%) of familial ALS
cases involving mutations in the SOD1 gene led to the
development of transgenic mouse models widely used for
testing possible drugs. The negative results of a variety of
approaches highlight the diﬀerences between human subjects
with ALS and any animal model [128]. Another recent
advance with regard to ALS therapeutics was the reported
improvement of SOD1 mutant mice as well as sporadic
patients under lithium treatment [129]. However, these
studies have raised some doubts concerning the design of
the clinical trial [130, 131]. Additionally, the results showed
in the animal model could not be replicated by another
group [132]. So far, no breakthrough has yet occurred in ALS
therapeutics and present thinking is that a combination of
drugs may be required to eﬀectively slow the multifactorial
neurodegenerative process [13].
A therapeutic approach based on the hypotheses of an
autoimmune pathogenic process should stop or at least mod-
ify disease progression. However, immunosuppressive drugs
such as corticosteroids, azathioprine, cyclophosphamide, or
combinations of them, as well as plasmapheresis therapy or
intravenous immunoglobulins (IVIG), have failed to aﬀect
the progression of the disease [7–11]. Sequential treatment
with plasmapheresis followed by an immunosuppressant
[cyclophosphamide, cyclosporine, and IVIG (Synchronized
immunosuppression therapy)] was reported to transiently
reduce electrophysiologic abnormalities at the neuromuscu-
lar junction of some ALS patients [133].
Although these negative results discourage this kind of
research, they should be analyzed considering that when the
patients are diagnosed with ALS, there are already patholog-
ical and physiological evidence that the disease is well estab-
lished, with massive loss of motor neurons [128]. Further-
more, little is known about the duration of any phase of
motor neuronal “sickness,” fromwhichmotor neurons could
be rescued by an eﬀective therapy. In addition, it must be
remembered that the success of any immunosuppressive
therapies is strongly aﬀected by the particular kind of auto-
immunity, the side eﬀects, and the general condition of
patients under treatment [134].
7. Autoimmunity as Pathogenic Mechanism
in ALS
A large body of evidence suggests the involvement of
autoimmunity as a pathogenic mechanism; however, the
present evidence data is not conclusive. Taken together, sev-
eral general conclusions can be drawn. First, the population
of patients with sporadic ALS is not homogenous and it is
clear that, if autoimmune mechanisms are pathogenic, this
finding cannot be generalized to the entire population of
sporadic ALS individuals. Second, abundance of research has
shown autoimmune mechanisms in ALS; however, it is not
clear if the autoimmune alterations are involved in the patho-
genesis or just appear as an epiphenomenon, particularly
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because immunosuppressive therapies have failed to suppress
or delay the disease. It is feasible that the antibodies directed
against intracellular antigens would not be pathogenic,
since antibodies for intracellular proteins appear to be
a byproduct of autoimmunity [110]. Experiments with the
autoimmune animal models strongly support autoimmunity
as a pathogenic mechanism, but an eﬀective therapy is still
required as a final proof. Third, the observation that the
IgG purified from a group of sporadic ALS patients, but not
familial ALS patients, specifically interacts with the presy-
naptic membrane of motoneurons and modulates synaptic
transmission through specific mechanisms also suggests that
ALS-Abs can be pathogenic [18]. Fourth, a major concern is
that the therapeutic approaches have failed [7–12]. However,
it is likely that these immunosuppressive therapies were not
appropriate.
Although it is diﬃcult to establish an eﬀective therapy for
any autoimmune disease, such as diabetes [134], in ALS, a
few issues such as the age of patients, alimentary diﬃculties,
and the advanced stage of the disease could make more
diﬃcult to obtain a positive response to therapy. However, if
ALS is caused by autoimmunity, we would expect that drastic
immunosuppression by total lymphoid irradiation (TLI)
produces an eﬀect in ALS patients [12]. In this study, no
change in the progression of the disease was observed. How-
ever, the authors found that, as expected, some parameters
of immune function were reduced by TLI treatment showing
adequacy of the immunosuppression but levels of antibodies
against gangliosides GM1 and GDlA were not reduced. These
findings illustrate that even the strongest approaches for
immunosuppression may have selective eﬀects and do not
necessarily inhibit all immune responses [12]. In addition,
we and others have documented that immunological mech-
anisms are capable of triggering long-lasting eﬀects [16–18,
35], suggesting that even in the absence of an active immuno-
logical noxious agent (e.g., ALS-Abs), the damage and/or
mechanisms leading to physiological deficits are already
established, without requirement of additional induction or
presence of such unknown pathogenic mechanisms.
Consistent with this notion, therapeutic trials aimed at
reducing oxidative stress and/or excitotoxicity mediated by
glutamate did not stop ALS progression [13, 135]. One
potential explanation is that, in all cases, when therapeutic
trials were performed, the disease was too advanced and may
be unsusceptible to be stopped or reversed. For instance,
a cyclooxygenase-2 (COX-2) inhibitor prolonged survival in
a SOD1 ALS model by slowing disease onset [121] but did
not alter progression after onset. Consistently, in a human
trial, this COX-2 inhibitor did not alter the progression
of ALS [136]. In fact, since it is the motor neuron loss
that provides the symptoms for ALS diagnosis [137], when
ALS patients are diagnosed, they already have a reduced
number of motor neurons [138–141]. This situation implies
that investigations on earlier detection will be essential for
therapeutic treatment of ALS.
In accordance with the idea that it is essential to identify
early events in the pathogenesis of ALS, next we depict an
autoimmune hypothesis focused on potential early events.
Briefly, autoantibodies against one ormore antigens at motor
nerve terminals bind to them triggering a signaling system
which includes Ca2+ influx and activation of Ryanodine and
IP3 receptors increasing [Ca2+]i, which modulates synaptic
transmission [18, 34]. Although ALS-Abs may also act in a
diﬀerent subcellular localization of motor neurons, we pro-
pose motor nerve terminals as primary and/or earlier target
since they are located outside the hematoencephalic barrier
and constitute a target for autoimmune response [142]. The
constitutive [Ca2+]i homeostasis deregulation may lead to
endoplasmic reticulum (ER) stress and/or mitochondrial
dysfunction with the consequent activation of apoptotic
pathways such as caspase 3 [14–17, 74]. These events may
lead to denervation and synaptic changes [35, 38, 54].
Additionally, injured neurons through secretion of proin-
flammatory eﬀectors may activate astrocytes which in turn
may promote further mitochondrial damage and apoptosis
in motoneurons [143]. Moreover, the hypothesis that the
neuronal damage is initiated in nerve terminals is consistent
with the observation that ALS is a motor neuron pathology
aﬀecting first distal axons in the SOD1 ALS mouse model as
well as in ALS patients [54, 143].
8. Perspectives
It is clear that there is a need for an eﬀective therapy to
interrupt the course of the disorder but also there is
a necessity for earlier diagnosis. An eﬀective therapy will
alleviate ALS patients and provide the strongest evidence
of the mechanisms involved, but an early diagnosis is still
required to treat ALS as soon as possible to assure a complete
recovery of motor functions.
Early diagnosis through biological markers seems to be
a tendency in ALS research and also a promising one. These
studies have discovered specific protein alterations detectable
in cerebrospinal fluid and blood as well as in tissues of ALS
subjects. High-throughput technologies have revealed sets
of proteomic or metabolic biomarkers that can discriminate
between ALS and control groups [144, 145]. However, vali-
dation of identified candidates is required.
Matrix metalloproteinases are a family of enzymes essen-
tial for organizing the extracellular matrix [146]. The detec-
tion of active matrix metalloproteinase-9 (MMP-9) by ELISA
(enzyme-linked immunosorbent assay) in serum from
patients with ALS and Guillain-Barre syndrome and its cor-
relation with nerve damage suggests that MMP-9 can be used
as an early marker in both disorders [147, 148].
Gene discovery and system biology tools applied to
ALS research seems to be another developing area. Since
it is suspected that the sporadic form of ALS is caused by
multiple genetic variants that individually make relatively
weak contributions to risk, genome-wide screens to asses
this hypothesis were proposed. Owing to the fact that this
approach requires a large sample size, collaborative eﬀorts
have created a public repository of human DNA, immortal-
ized cell lines, and clinical data to facilitate gene discovery
in ALS, http://ccr.coriell.org/Sections/Collections/NINDS/?
SsId=10[149]. This resource currently maintains samples
and associated phenotypic data from thousands of motor
neuron disease and control subjects.
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On the other hand, some perspectives and tendencies
in ALS research may quickly turn in accordance with suc-
cessful results from ongoing clinical trials. The US National
Institutes of Health lists 61 clinical trials for ALS currently
recruiting volunteers. For instance, it includes studies aimed
at assessing the feasibility and security of the intraspinal
infusion of autologous bone marrow stem cells for the
treatment of ALS patients (ClinicalTrials.gov identifier:
NCT00855400).
To date, our understanding of autoimmune mechanisms
in ALS is limited to correlations between manifestation of
ALS and immunological alterations, and structural and phys-
iological modifications after treatment with ALS-Abs. How-
ever, the autoantigens involved and the underlying mecha-
nisms that induce the generation of such autoantibodies are
still not known. The identification of the auto-antigens will
allow us to not only develop specific animal models, but also
to design rational therapies for specific molecular targets,
further characterizing the role of autoimmune mechanisms
and developing biochemical tests for early detection of ALS.
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